Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CFD | P00746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13014755 | 0.99 | LMNA (0.50) | KCNH2TSHRLMNAMEN1ALDH1A1 | |
| SCHEMBL13014702 | 0.91 | ALDH1A1 (0.53) | KCNH2TSHRLMNAMEN1ALDH1A1 | |
| SCHEMBL5994789 | 0.89 | LMNA (0.49) | KCNH2TSHRLMNAMEN1ALDH1A1 | |
| SCHEMBL8520410 | 0.88 | LMNA (0.51) | KCNH2TSHRLMNAMEN1ALDH1A1 | |
| SCHEMBL17527195 | 0.85 | KCNH2 (0.56) | KCNH2TSHRLMNAMEN1ALDH1A1 | |
| SCHEMBL13014739 | 0.83 | DPP4 (0.58) | KCNH2CFDCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3733552 | 0.83 | LMNA (0.52) | TSHRLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL17220302 | 0.81 | GAA (0.54) | TSHRLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL27828766 | 0.81 | GAA (0.54) | TSHRLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL13014705 | 0.81 | KCNH2 (0.49) | KCNH2CFDCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885TSHR 4834/4885LMNA 3118/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885TSHR 4834/4885LMNA 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.